BioMarin Pharmaceutical Inc.
NASDAQBioMarin Pharmaceutical enters the back half of May with an unusual split: the Street is broadly bullish, Goldman Sachs just stepped off the buy side, and short sellers have been adding with quiet persistence. The analyst picture this week is the headline story. Goldman Sachs reinstated coverage on May 11 with a Neutral and a $69 target — down from a prior Buy — a meaningful step…
BMRN cost to borrow surges 178% in one week to 0.33%, lowest level on record but sharply reversing from recent lows.
Snapshot as of 22 Jun 2026
BioMarin Pharmaceutical enters the back half of May with an unusual split: the Street is broadly bullish, Goldman Sachs just stepped off the buy side, and short sellers have been adding with quiet persistence. The…
BioMarin Pharmaceutical heads into its May 4 Q1 earnings report with short sellers at their most committed in months — a notable shift for a stock where positioning had been relatively relaxed for much of the first…
Short sellers ramped up positions ahead of BMRN's Q1 print. Options traders show strong call bias, suggesting near-term bullish sentiment despite the bearish positioning. Short interest stands at 8.97 million shares,…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BMRN — free to start on ORTEX.
Sign up for free →Open BMRN on ORTEX